Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR)
antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the …

Therapeutic medications for the treatment of depression have serious limitations, particularly
delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic …

Abstract Glycogen synthase kinase 3 (GSK-3) dysregulation plays an important role in the
pathogenesis of numerous disorders, affecting the central nervous system (CNS) …

Despite the continuous advancement in neurosciences as well as in the knowledge of
human behaviors pathophysiology, currently suicide represents a puzzling challenge. The …

ObjectiveAlthough monoaminergic-targeted drugs have prompted great advances in the
development of treatments for depression, the need for new options persists, since these …

Objective: The N-methyl-d-aspartate receptor antagonist ketamine produces rapid and
sustained antidepressant actions even in patients with treatment-resistant depression …

Parkinson's disease (PD) is one of the major neurodegenerative diseases (ND) which
presents a progressive neurodegeneration characterized by loss of dopamine in the …

Neurodegenerative diseases (NDDs) pose an increasingly prevalent threat to the well-being
and survival of elderly individuals worldwide. NDDs include Alzheimer's disease (AD) …

GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties
that produces rapid antidepressant effects, but without the psychotomimetic side effects of …